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he Best “Model
ystem” for Human
Coronary Arteries) Is Human*
scar Ö. Braun, MD, PHD,† Paul A. Insel, MD†‡
a Jolla, California
esearch in cardiovascular medicine (and other areas) has
ncreasingly emphasized the use of “model organisms” as a
eans to assess physiology, pathophysiology, and therapy of
isease. Indeed it is ironic that certain journals (including
high impact” ones that have the words “clinical” or “med-
cine” in their names and whose content focuses on disease
echanisms) have, especially in recent years, primarily
ublished studies that were not conducted on human beings
r human tissues. There are many reasons why investigators
nterested in human disease use experimental (model) sys-
ems, including the difficulty of doing in vivo studies in
umans and the limited accessibility/availability of fresh
uman tissue, especially of normal tissue. This is a particular
roblem in studies that focus on the heart, because tissue
vailability is generally limited to samples obtained intraop-
ratively or at autopsy.
See page 1137
In this regard, a PubMed search with the term “adren-
rgic receptors”—the cell surface receptors that mediate
ctions of the physiologic agonists norepinephrine and
pinephrine and of a wide variety of pharmacologic agonists
nd antagonists—yields almost 50,000 “hits,” but the vast
ajority of those articles describe results of studies in
xperimental animals or with cultured cells. Thus, most of
he knowledge and ideas regarding adrenergic receptors
erives from research on systems of questionable rele-
ance to the in vivo setting in humans. How valid for
umans are conclusions that are drawn from such mod-
ls? What are the differences and similarities between
odent models, for example, and humans? Is there 1
nimal model that best mirrors what transpires in humans
n terms of normal physiology and disease settings?
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.q
From the Departments of †Pharmacology and ‡Medicine, University of California
an Diego, La Jolla, California.ltimately, data in humans will be required for new
iagnostics and therapeutics.
It is thus of considerable interest that, in this issue of the
ournal, Jensen et al. (1) provide novel data and information
hat advance understanding of adrenergic receptors in hu-
an coronary vessels. Because the authors used human
essels and conducted careful studies with samples from
iseased and healthy hearts, the study is unusual and an
mportant contribution. The findings also provide a ratio-
ale for the development of new drugs and agents to assess
oronary artery physiology and pathophysiology.
It is widely recognized that there are 9 subtypes of
drenergic receptors (adrenoceptors) in humans: 1A,
1B, and 1D; 2A, 2B, and 2C; and 1, 2, and 3,
ach of which is encoded by a separate gene. A large number
f studies have sought to define the expression and role of
drenergic receptor subtypes in the heart. Figure 1 summa-
izes the expression pattern of adrenergic receptors in
uman heart (1–3).
Most previous efforts on the heart have been devoted to
-adrenergic receptors. The 1-adrenegic receptors pre-
ominate in cardiac myocytes in mammals (4), although
ttention in recent years has also been directed at 2- and
3-adrenergic receptors and their roles in certain cardiac
unctions (4,5). Other efforts have emphasized whether
enetic variants in human -adrenergic receptors influence
isease susceptibility or intersubject variability in cardiovas-
ular physiology or drug responses (6,7). The wide use and
mportance of -blockers in the therapy of cardiovascular
isorders provides a continuing impetus for studies of the
olecular and cell biology, physiology, and pharmacology of
-adrenergic receptors.
Relatively less attention has been directed at cardiac
-adrenergic receptors and, in particular, 1-adrenergic
eceptors. The most abundant messenger ribonucleic acid in
uman hearts among the 1-receptors is that of 1A-
eceptors, but at the protein level 1B-receptors predomi-
ate in both human and rodent hearts (1,8–10). A recent
eport assessed hearts from 8-week-old mice and revealed
he expression of a broad range of G-protein–coupled
eceptors (GPCRs) in the 4 cardiac chambers; the authors
ound that atria preferentially express GPCRs different from
hose in ventricles and that the 2 ventricles express similar
evels of 13 GPCRs (11). The latter include adrenergic
eceptors, which are expressed at the following relative
bundance: 1B  1A  2B and 1  2, with 2
niformly expressed throughout the heart. It will be of
nterest to learn whether human hearts show similar results
n cardiac regions and cell types, including in coronary
essels.
Over 25 years ago Dr. Simpson, the senior author of the
ensen et al. (1) paper, discovered that -adrenergic recep-
ors induce and regulate cardiac hypertrophy (12). Subse-
uent studies have shown that 1-adrenergic receptors in
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September 22, 2009:1146–8 “Model System” for Human Coronary Arteriesardiac myocytes can have a protective role in maintaining
ardiac function and preventing maladaptive remodeling
fter cardiac stress (13). Adrenergic signaling also regulates
he tone of the coronary arteries: -adrenergic receptors
romote constriction and a decrease in coronary artery blood
ow, whereas -adrenergic receptors have opposite effects.
urprisingly, however, relatively little attention has been
irected at defining the precise pharmacology and clinical
tility of -adrenergic receptors in the coronary circulation.
lpha-blockers have thus lived “in the shadow” of blockers
f their -adrenergic receptor “cousins” in terms of
egulation of the coronary circulation. The -blockers
ave unexpected effects on coronary blood flow: blocking
–receptor–mediated vasodilation would be predicted to
ncrease vascular tone and decrease flow, but the opposite
ffect is observed after treatment with -blockers (14).
uch -blocker–promoted effects on coronary flow per-
aps result from reduced myocardial oxygen consumption
nd prolongation of diastole, thereby increasing the time
f coronary arterial perfusion. In the study by Jensen et al.
1) coronary arteries of patients treated with -blockers
ad a decreased number of 1D receptors. Because 1D
eceptors promote vasoconstriction, a decrease in their
umber might contribute to the beneficial effect of
-blockers on coronary blood flow.
In addition to results regarding messenger ribonucleic
cid and protein expression of -adrenergic receptors in
uman coronary arteries, Jensen et al. (1) also provide
unctional data on receptor-promoted activation of extracel-
ular signal-regulated kinase (ERK) activity. The choice of
RK phosphorylation as the readout for -adrenergic
timulation is not ideal. The mechanism by which ERK
hosphorylation occurs after GPCR stimulation is not
dequately defined and might involve transactivation of
pidermal growth factor receptors and/or direct activation of
Figure 1
Expression of 1- and
-Adrenergic Receptors in Human
Coronary Artery and Left Ventricular Myocardium
Summary of the relative expression levels of - and -adrenergic receptors
in human coronary artery and left ventricular myocardium on the basis of
results in the studies by Jensen et al. (1), Bristow et al. (2), and Steinfath
et al. (3).RK by heterotrimeric G-protein–derived G subunits
115). As an alternative, one might assess a more proximal
-adrenergic receptor response (e.g., activation of Gq
nd/or phospholipase C, both of which are triggered by
uch activation or of “early” downstream signals, such as
hanges in cytosolic Ca2 levels or protein kinase C
ctivation). In addition, propranolol, which Jensen et al.
sed to block -adrenergic receptors, can induce a partial
gonistic response for ERK activation (16). It would thus
ave been informative to confirm the results with propran-
lol by use of an alternative -blocker.
Overall, the study by Jensen et al. (1) provides important
ew data regarding expression of -adrenergic receptors in
uman coronary arteries. Comparison of results with what is
nown for expression of those receptors in coronary arteries
f other commonly used experimental animals (Table 3 in
ensen et al. [1]) emphasizes that not all such animals reflect
he setting in humans. Thus, humans are thus likely the best
model system” for studies of adrenergic receptors in human
oronary arteries. More widespread recognition of this
oncept and of the findings in the study by Jensen et al. (1)
hould encourage the development of new approaches for
he diagnostic evaluation and therapeutic targeting of
-adrenergic receptors (and perhaps other GPCRs) in
uman coronary arteries.
eprint requests and correspondence: Dr. Paul A. Insel, Uni-
ersity of California, San Diego, BSB 3076, 9500 Gilman Drive–
636, La Jolla, California 92093. E-mail: pinsel@ucsd.edu.
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